Transdermal Drug Delivery Systems (TDDS) are self-contained, discrete dosage forms. When applied to intact skin, they deliver drugs at a controlled rate directly to the systemic circulation — bypassing the hostile environment of oral administration entirely.
Unlike topical formulations which treat the skin itself, TDDS uses the skin merely as a portal to the bloodstream. By engineering formulations that navigate the Stratum Corneum and utilise the Dermal blood supply, Hoshi MedTech achieves systemic therapy without the invasiveness of needles or the variability of digestion.
Our patch technology represents a convergence of polymer science, pharmacokinetics, and patient-centric design — resulting in treatments that are not only clinically superior but genuinely easier for patients to integrate into daily life.
Bypasses liver metabolism entirely for maximum drug bioavailability and consistent systemic dosing.
Provides consistent plasma concentration — ideal for drugs with narrow therapeutic windows.
Eliminates injections and GI exposure — dramatically improved patient experience and compliance.
Therapy can be immediately stopped by removing the patch — unmatched clinical flexibility.
Why it matters: Understanding the difference between topical and transdermal delivery is critical in clinical pharmacology — one stays local, the other achieves systemic therapeutic concentrations throughout the body.
Local tissue effect
Systemic bloodstream entry
TDDS represents a precise balance of chemistry and biology. By engineering formulations that can navigate the Stratum Corneum and utilize the Dermal blood supply, we achieve systemic therapy without the invasiveness of needles or the variability of digestion.